Cycopin (Mycophenolate Mofetil)

“Enhance Immunosuppression”

Cycopin (Mycophenolate Mofetil) is the mofetil ester of mycophenolic acid (MPA), the active immunosuppressant. Mycophenolic Mofetil (MMF) is used in combination with a Calcineurin inhibitor like Tacrolimus or cyclosporine plus steroids to prevent rejection in organ transplant. Mycophenolic Mofetil (MMF) therapy is often initiated at the time of transplant, but it is sometimes added to the Immunosuppression regimen following the 1st episode of acute rejection Biocare Pharmaceutica is the only company in Pakistan that is currently marketing Cycopin in 250 mg strength.


Cycopin (Mycophenolate Mofetil) is an immunosuppressant drug used to prevent rejection in organ transplantation like kidney, liver, bone marrow and heart. Off-label Cycopin (Mycophenolate Mofetil) is also widely used in Nephrotic syndrome especially in pediatric patients. Cycopin (Mycophenolate Mofetil) is also beginning to be used in the management of auto-immune disorders such as idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), scleroderma (systemic sclerosis or SSc), and pemphigus vulgaris (PV) with success for some patients.

Dosage Guidelines:

The recommended dose for Cycopin (Mycophenolate Mofetil) is 1 g PO/IV q12hr, infused over ≥2 hours (2 gm per day) or 1.5 g PO/IV q12hr, infused over ≥2 hours (3 gm per day) depending upon organ transplant.


Cycopin (Mycophenolate Mofetil) is available in 250 mg dispersible tablet in 10X4 ‘S Pack.

Biocare Pharmaceutica Sales Trend (2005-2015)